Inflammation-linked adaptations in dermal microvascular reactivity accompany the development of obesity and type 2 diabetes by Nguyen-Tu, Marie-Sophie et al.
HAL Id: hal-02108186
https://hal.archives-ouvertes.fr/hal-02108186
Submitted on 19 Jun 2020
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution| 4.0 International License
Inflammation-linked adaptations in dermal
microvascular reactivity accompany the development of
obesity and type 2 diabetes
Marie-Sophie Nguyen-Tu, Pierre Nivoit, Valérie Oréa, Sandrine Lemoine,
Cécile Acquaviva, Aurélie Pagnon-Minot, Bérengère Fromy, Jaswinder Sethi,
Dominique Sigaudo-Roussel
To cite this version:
Marie-Sophie Nguyen-Tu, Pierre Nivoit, Valérie Oréa, Sandrine Lemoine, Cécile Acquaviva, et al..
Inflammation-linked adaptations in dermal microvascular reactivity accompany the development of
obesity and type 2 diabetes. International Journal of Obesity, Nature Publishing Group, 2019, 43 (3),
pp.556-566. ￿10.1038/s41366-018-0148-4￿. ￿hal-02108186￿
International Journal of Obesity (2019) 43:556–566
https://doi.org/10.1038/s41366-018-0148-4
ARTICLE
Animal Models
Inflammation-linked adaptations in dermal microvascular reactivity
accompany the development of obesity and type 2 diabetes
Marie-Sophie Nguyen-Tu1,2 ● Pierre Nivoit1,2 ● Valérie Oréa1,2 ● Sandrine Lemoine2 ● Cécile Acquaviva1,3 ●
Aurélie Pagnon-Minot4 ● Bérengère Fromy1,2 ● Jaswinder K. Sethi 5,6,7 ● Dominique Sigaudo-Roussel1,2
Received: 4 January 2018 / Revised: 26 May 2018 / Accepted: 8 June 2018 / Published online: 13 July 2018
© The Author(s) 2018. This article is published with open access
Abstract
Background/Objectives The increased prevalence of obesity has prompted great strides in our understanding of specific
adipose depots and their involvement in cardio-metabolic health. However, the impact of obesity on dermal white adipose
tissue (dWAT) and dermal microvascular functionality remains unclear. This study aimed to investigate the temporal
changes that occur in dWAT and dermal microvascular functionality during the development of diet-induced obesity and
type 2 diabetes in mice.
Methods Metabolic phenotyping of a murine model of hypercaloric diet (HCD)-induced obesity and type 2 diabetes was
performed at three time points that reflected three distinct stages of disease development; 2 weeks of HCD-overweight-
metabolically healthy, 4 weeks of HCD-obese-prediabetic and 12 weeks of HCD-obese-type 2 diabetic mice. Expansion of
dWAT was characterized histologically, and changes in dermal microvascular reactivity were assessed in response to
pressure and the vasodilators SNP and Ach.
Results HCD resulted in a progressive expansion of dWAT and increased expression of pro-inflammatory markers (IL1β
and COX-2). Impairments in pressure-induced (PIV) and Ach-induced (endothelium-dependent) vasodilation occurred early,
in overweight-metabolically healthy mice. Residual vasodilatory responses were NOS-independent but sensitive to COX
inhibition. These changes were associated with reductions in NO and adiponectin bioavailability, and rescued by exogenous
adiponectin or hyperinsulinemia. Obese-prediabetic mice continued to exhibit impaired Ach-dependent vasodilation but PIV
appeared normalized. This normalization coincided with elevated endogenous adiponectin and insulin levels, and was
sensitive to NOS, COX and PI3K, inhibition. In obese-type 2 diabetic mice, both Ach-stimulated and pressure-induced
vasodilatory responses were increased through enhanced COX-2-dependent prostaglandin response.
Conclusions We demonstrate that the development of obesity, metabolic dysfunction and type 2 diabetes, in HCD-fed mice,
is accompanied by increased dermal adiposity and associated metaflammation in dWAT. Importantly, these temporal
changes are also linked to disease stage-specific dermal microvascular reactivity, which may reflect adaptive mechanisms
driven by metaflammation.
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Introduction
With the increased prevalence of obesity and type 2 dia-
betes, and limited success in preventative approaches, there
is an urgent need to better understand and manage the long-
term consequences of metabolic disease [1]. Obesity com-
plications include skin disorders that may increase the
prevalence of more severe pressure ulcers (PU) [2, 3]. For
example, obesity is associated with decreased tensile
strength [4] and dermal elasticity in mice [5] and humans
[6]. However, an ‘obesity paradox’ has also been reported
wherein people with a body mass index (BMI) between 25
and 40 appear to be protected from the development of PU
[7]. Indeed, we have recently found that in a murine model
of diet-induced obesity, pressure-induced ischaemia and
skin lesions are reduced with increasing obesity [8]. This
suggests that pressure-induced regulation of cutaneous
blood flow may be altered by changes in dermal adiposity.
However, this and the underlying mechanisms currently
remain unclear. In addition, none of the clinical studies
focused on PU incidence have assessed the metabolic status
of the obese subjects under investigation. Hence, the impact
of increased dermal adiposity per se, or that of the metabolic
deregulation that accompanies obesity-linked type 2 dia-
betes, on vascular fragility of the skin remains unclear.
Mechanistically, numerous features of obesity-associated
metabolic deregulation could impact dermal microvascular
functionality through local paracrine interactions with
expanding adipose tissue. These include obesity-associated
impaired metabolic functionality of adipose tissue, altered
adipokine production [9] and low-grade chronic inflamma-
tion (metaflammation) [9–11]. Some of these have been
implicated in perivascular adipose tissue-mediated, endo-
thelial cell dysfunction in arteries and arterioles [12, 13].
Another major causal feature of obesity-linked type 2 dia-
betes is insulin resistance, which induces endothelial dys-
function in vascular disease via an inadequate production of
endothelial NO and endothelin-1 [14, 15]. Among the
dermal changes linked to diabetes [1], the disruption of
microvascular adjustment to pressure, as revealed by
pressure-induced vasodilation (PIV), correlates with
increased vascular fragility of the skin [16–19]. Type 2
diabetic patients also exhibit a range of vascular, oxidative
stress and inflammatory changes [20] that may affect skin
and neurovascular quality [21, 22]. The potential impact of
obesity-linked type 2 diabetes on the arterial micro-
environment [23] could affect microvascular adjustment to
pressure in a context-dependent manner, by changes in
adiposity, followed by progressive changes in metabolic
dysfunction prior to the establishment of type 2 diabetes.
In this study, we investigate the temporal changes in
dermal adiposity, dermal microvascular functionality and in
endothelial function during the development of obesity and
type 2 diabetes. We hypothesize that remodelling of dermal
adipose layer and the development of type 2 diabetes are
linked to changes in dermal microvascular reactivity to
pressure. Our findings suggest that initially, at the onset of
increased adiposity, alterations in neurovascular and endo-
thelial function are associated with altered adipokine pro-
duction. However, as obesity progresses to pre-diabetic and
diabetic states, additional adaptions occur to normalize and
then enhance dermal vascular reactivity to pressure.
Mechanistically, these adaptive changes involve a shift in
key vasodilatory signalling pathways from a NO-dependent
to pro-inflammatory COX-2/PG-driven programmes.
Research design and methods
Animals
Male C57Bl/6J mice (aged 10 weeks and approximately
25 g from Janvier®, Le Genest-Saint-Isle, France) were
acclimated for 1 week prior to start of the study. All animal
procedures were carried out in accordance with the princi-
ples of French legislation and the ethics committee for
animal experimentation at the University of Lyon 1, France.
Mice were housed five per cage, maintained at 21 °C, on a
12-h light/dark cycle and at 11 weeks of age were randomly
divided into six groups. Mice were placed on either a nor-
mal chow diet (control) or an obesogenic hypercaloric diet
(HCD) for a further 2, 4 or 12 weeks. The energy-rich diet
pellets comprised of 45% Atwater fuel energy (AFE) from
fat and 16% AFE from sucrose (total energy 4.5 kcal/g;
SDS DIO diet cat# 824127, Essex, UK), and was further
supplemented with ad libitum access to sweetened con-
densed milk (55% simple sugar, 8% fat, 8% protein, w/w,
Nestle®) as previously described [8, 24, 25]. Three time
points of HCD feeding were identified to represent three
distinct stages of disease progression: (a) an early point
(2 weeks of HCD, 2HCD) when HCD fed mice first become
significantly heavier but fasting glucose remained unaltered,
(b) an intermediate point (4 weeks of HCD, 4HCD) when
body weight was increased further, but fasting glucose
levels were significantly albeit mildly elevated to pre-
diabetic levels (see definition below) and (c) a final time
point (12 weeks of HCD, 12HCD) when body weight dif-
ferences were at their greatest and fasting glucose levels
were considered diabetic.
Glucose and insulin tolerance tests
After 2, 4 and 12 weeks of diet, glucose and insulin tolerance
tests were performed on 5 h-fasted mice after an intraper-
itoneal (ip) injection of either glucose (1 g kg−1 of body
weight) for glucose tolerance test or insulin (0.75 U kg−1 of
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body weight; Lilly, Suresnes, France) for insulin tolerance
test. Blood glucose was monitored for 2 h with a glucometer
(AccuCheck® Active; Roche, Lyon, France). Mice with
baseline fasting blood glucose levels >250mg/dL were con-
sidered to be diabetic, while levels between 200 and 250mg/
dL were defined as prediabetic and <199mg/dL were normal
[26, 27].
Assessment of dermal microvascular reactivity
For microvascular experiments, animals were anesthetized
by ip injection of thiopental sodium (65 mg kg−1; Nesdonal,
Merial, Lyon, France) and mice, in prone position, were
rested in an incubator with controlled dermal temperature
and systolic arterial blood pressure as previously described
[28]. Any skin lesion on the animal the day of the experi-
ment led to exclusion.
Endothelium-dependent and independent vasodilation
Laser Doppler flux (LDF) in response to acetylcholine
(Ach) and sodium nitroprusside (SNP) (Saint Quentin Fal-
lavier, France) iontophoresis was measured to assess skin
microvascular reactivity on the hairless back of the animals
as previously described [19, 28].
Pressure-induced vasodilation
Local pressure-induced LDF response was measured as
previously described [19, 28]. The pressure probe was
placed on hairless skin of the top of the head, and the
external pressure was increased progressively at 2.2 Pa s−1
through the laser Doppler probe, using a syringe pump.
Pharmacological inhibition studies
Stimulated vasodilation was assessed after pretreatment
with DMSO (control), wortmannin to inhibit phosphatidy-
linositol 3-kinase (PI3K) or Nω-nitro-L-arginine (LNNA),
an NO synthase (NOS) inhibitor. Systolic arterial blood
pressure was measured to check the increase in blood
pressure caused by LNNA, a specific NOS inhibitor
(20 mg kg−1; ip) [28]. For wortmannin injection (in 4%
DMSO; 16 µg kg−1; ip), the protocol was conducted as
described above after a resting period of 15 min [29].
Indomethacin (5 mg kg−1; i.p.), was used as a non-specific
inhibitor of cyclooxygenases (COX) [30, 31] while specific
inhibition of inducible COX-2 (Cayman Chemicals, MI,
USA) was achieved with SC-58125 (10 mg kg−1; i.v.) [32].
The role of insulin and adiponectin in PIV was assessed by
either a single ip injection of insulin (0.05 UI 25−1 g of
mouse body weight; Lilly, Suresnes, France) or a single
intradermic injection of adiponectin (50 µg.mL-1; Enzo
LifeSciences, Farmingdale, NY). Assessment of PIV was
conducted 15 min after insulin injection and immediately
after adiponectin injection.
At the end of vascular experiments, the animals were
euthanized by an overdose of thiopental.
Plasma biochemistry
Plasma was obtained by cardiac puncture and was analysed
by the Centre de Biologie Est (Lyon, France) for lipids
(cholesterol/triglyceride, Abbott Laboratories, Abbott Park,
IL; free fatty acid, Wako Chemicals, Osaka, Japan), com-
mercial colorimetric ELISA assays were used for determi-
nation of plasma insulin (Mercodia, Uppsala, Sweden) and
adipokines (leptin/adiponectin, Millipore, St. Charles, MO)
according to manufacturer’s protocol.
Western blotting
Immunoblotting using anti-COX-2 (Cayman Chemicals,
#160126) was performed on skin harvested from each
group. Pharmacological drugs efficiency was confirmed
by immunoblotting using anti-phospho-eNOS-Ser1177,
anti-phospho-Akt-Ser473 (Cell signalling Technology;
Danvers, MA) on treated skin harvested at the maximum
of PIV.
Immunohistochemistry and morphometric analysis
Mouse skin specimens were fixed with neutral buffered
formalin, dehydrated, embedded in paraffin and cut in 5 μm
sections. For the histological analysis, sections were label-
led with hematoxylin–eosin–safran. For the immunohisto-
logical study, deparaffinized and rehydrated tissue sections
were pretreated with citrate buffer (pH= 6.0). Incubation
with primary antibodies (anti-F4/80 [Sigma, HPA002274]
and anti-IL-1β [Abcam ab9722]) was followed by blocking
of endogenous peroxidase activity with 0.5% aqueous
H2O2. After incubation with HRP-conjugated secondary
antibodies, sections were revealed with diaminobenzidine,
counterstained with Mayer’s hematoxylin and observed
using a DM 4000B microscope (Leica) coupled to a colour
camera (Digital Camera DXM1200, Nikon). Image acqui-
sition was achieved using Metaview software (Universal
Imaging). Measurements of adipocyte number and area
(µm2) was performed from hematoxylin–eosin–safran-
stained histological sections. Histological images (G:x20,
5 pictures/sample, n= 4/group) were captured using a wide
field optical microscope, then analysed to count the number
and the area of each adipocyte. The sequence of image
analysis steps was automatically implemented by Adiposoft
1.14 in Manual Mode. This software was calibrated based
on the magnification used during image acquisition. The
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number and area (in µm2) occupied by each adipocyte was
automatically calculated by Adiposoft software.
Statistical analysis
Investigators were not blinded to treatment and data ana-
lysis. Statistical analysis was done using GraphPad Prism
software (GraphPad Software, Inc., San Diego, CA). The
data is reported as mean ± standard error of the mean
(SEM). Shapiro and Wilks goodness-of-fit test was used to
test for normal distribution. Variance was assessed for each
dependent variable measured. Statistically significant dif-
ferences were calculated by one-way analysis of variance
(followed by Duncan’s post-test) or unpaired Student’s
t-test; p < 0.05 was considered statistically significant.
Sample size for each test was based on previous studies
using mice models.
Results
Temporal phenotyping of diet-induced obesity
reveals specific stages of metabolic disease
development and acute changes in adiponectin
levels
Body weight was significantly elevated early at 2 weeks
after HCD feeding and continued to increase with duration
on HCD diet compared to age-matched control mice
(Fig. 1a). This was accompanied by greater caloric intake
(Fig. 1b) and progressively greater adiposity in inguinal
subcutaneous (Fig. 1c) and epididymal (Fig. 1d) adipose
depots. This coincided with an early and progressive
increase in adiposity-related adipokine, leptin (Fig. 1e).
However, circulating triglycerides and non-esterified fatty
acids did not change until 12 weeks after the start of HCD
feeding (Table S1).
There was an incremental development of type 2 diabetes
in this model. After 2 weeks of HCD, plasma adiponectin
levels (Fig. 1f) were lower but mice remained euglycemic,
and no differences were observed in plasma insulin levels
(Table S1), glucose tolerance (Fig. 1g and Fig. S1A) or
insulin tolerance (Fig. 1h and Fig. S1B). Hence, this 2-HCD
group represented a model of ‘overweight-metabolically
healthy’ mice albeit with reduced adiponectin. After
4 weeks, 4-HCD mice were obese and had normalized
adiponectin levels (Fig. 1f) and were very mildly hyper-
insulinemic and hyperglycemic (Table S1). Both glucose-
(Fig. 1g and Fig. S1C) and insulin- (Fig. 1h and Fig. S1D)
tolerance were also mildly impaired compared to age-
matched control diet fed mice. Hence, this 4-HCD group
represented a model of ‘obese-prediabetic’ mice. Lastly, 12-
HCD mice exhibited the greatest levels of obesity,
hyperglycaemia, hyperinsulinemia and hyperlipidaemia
(Table S1) together with impaired glucose- and insulin-
tolerance. (Fig. 1g, h and Fig. S1E-F). Hence, these mice
exhibited an established disease stage characteristic of
‘obesity and type 2 diabetes’.
It is noteworthy that control diet fed lean mice also
exhibited time-dependent alterations in their metabolic
profiles that became significant after 12 weeks. The changes
included a small but significant increase body weight
(Fig. 1a, Table S1) and food intake (Fig. 1b), but did not
translate into significantly larger WAT depots (Fig. 1c, d)
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Fig. 1 Effect of HCD on the development of obesity and metabolic
syndrome. Mice were fed either hypercaloric diet (filled circles and
bars) or standard chow (open circles and bars) for 2, 4 or 12 weeks.
a Body weight of mice during the 12-week feeding programme.
b Calorie intake of control and HCD fed mice. c Subcutaneous white
adipose tissue (ScWAT) weights. d Epididymal white adipose tissue
(EpiWAT) weights. e Circulating leptin levels. f Circulating adipo-
nectin (AdipoQ) levels. g Area under the curve (AUC) of glucose
levels during glucose tolerance tests (IP-GTT) and h Insulin tolerance
tests (IP-ITT). See also Supplemental Fig. 1. Data represents mean ±
SEM (n= 10 in each group or n= 50 in each group for body weight)
*p < 0.05, **p < 0.01, ***p < 0.001 vs. age-matched control diet fed
mice. †p < 0.05, ††p < 0.01, †††p < 0.001 vs. 2-week control diet fed
mice
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nor increased plasma leptin (Fig. 1e). The oldest lean mice
remained tolerant to both glucose (Fig. 1g) and insulin
(Fig. 1h). However, plasma adiponectin levels did pro-
gressively decline (Fig. 1f) and mild fasting hyperglycaemia
was observed by 12 weeks (Table S1).
Remodelling of dWAT accompanies the
development of HCD-induced obesity
In HCD-fed mice, the dermal adipose layer [33] was already
expanded at the earliest time point (Fig. 2a, b). The dWAT
occupied greater area with time on HCD (Fig. 2a, b and Fig.
S2A) and was accompanied by a progressive increase in both
adipocyte hyperplasia and hypertrophy compared to control
diet fed mice (Fig. 2a and Fig. S2B). Immunohistochemical
staining for macrophages (anti-F4/80) and pro-inflammatory
cytokines (anti-IL-1β) revealed a progressive increase in mac-
rophage infiltration after 4 weeks (Fig. 2a). In 12-HCD mice,
there was a noticeable clustering of pro-inflammatory (M1-like)
macrophages in ‘crown-like’ structures. In skin biopsies, the
protein levels of inflammation-associated COX-2 also pro-
gressively increased with increased dermal adiposity (Fig. 2c
and Fig. S2C). However, there was no change in the structure
of the dermal vessels in HCD and control mice (Fig. 2a).
Dermal microvascular functionality is altered in a
disease-stage-specific manner
We next investigated the temporal changes in dermal blood
flow. Basal LDF increased with the duration on HCD diet
and when corrected for systemic arterial blood pressure
(SABP), the vascular conductance (VC) remained sig-
nificantly increased in 12-HCD mice (Fig. S3). In 2-HCD
mice, the LDF response to local pressure application was
significantly reduced compared to age-matched control lean
mice (Fig. 3a). However, this PIV response appeared nor-
malized in 4-HCD mice, and was significantly increased in
12-HCD mice compared to age-matched lean controls. In
contrast, maximal SNP-stimulated (endothelium-indepen-
dent) vasodilation remained similar between HCD and
control groups (Fig. 3b) in all groups, suggesting dermal
smooth muscle cell relaxation capacity is not altered during
the development of obesity and type 2 diabetes. However,
Ach-stimulated (endothelium-dependent) vasodilation was
impaired at an early disease-stage, in both 2-HCD and 4-
HCD mice (Fig. 3c). Remarkably, 12-HCD mice exhibited a
greater vasodilatory response to Ach, which was due in part,
to a reduction in Ach-stimulated vasodilation in control lean
mice (Fig. 3c) that may reveal temporal endothelial
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dysfunction similar to 2-HCD mice. However, cholesterol
levels remained in the normal range in all groups excluding
any confounding effect of hypercholesterolaemia linked to
obesity/type 2 diabetes on microvascular changes.
Impaired PIV and endothelial dysfunction in
overweight-metabolically healthy mice is associated
with loss of NO and adiponectin bioavailability
We next investigated the mechanisms responsible for the
early impairment in PIV and Ach-stimulated endothelial
function in overweight-metabolically healthy (2-HCD) mice.
Unlike its effects in control lean mice, the NOS inhibitor,
LNNA had no effect on either PIV- (Fig. 4a, b) or Ach-
(Fig. 4c, d) stimulated vasodilation in 2-HCD mice. This
suggests that NOS-dependent vasodilation is lost. The PI3K
inhibitor, wortmannin, had no effect on both vasodilatory tests
in both diet groups (Fig. 4a–d). However, western blotting for
phosphoactive-AKT and phosphoactive-eNOS confirmed that
these inhibitors were effective at the molecular level (Fig. S4).
Additionally, treatment with indomethacin, a COX-1/2
inhibitor, demonstrated that residual vascular functionality in
2-HCD mice, was sensitive to prostaglandin-dependent sig-
nals (Fig. 4a–d).
Since the additional requirement for prostaglandin-
dependent vasodilation coincided with a decrease in the
anti-inflammatory adipokine, adiponectin (Fig. 1f), we
hypothesized that reduced PIV in 2-HCD mice was due to
reduced adiponectin bioavailability. This was supported by
the complete reversal of impaired PIV response following a
single injection of adiponectin in 2-HCD mice (Fig. 4e). As
adiponectin also has insulin-sensitizing properties [34], 2-
HCD mice were next pre-treated with insulin supple-
mentation prior to PIV determination. This pre-treatment
raised plasma insulin levels to 9.37 ± 1.7 µg/L (p < 0.001)
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§p < 0.05, §§p < 0.001, §§§§p < 0.00001 vs. 2-week hypercaloric diet fed
mice
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and did not alter basal LDF (data not shown). However,
elevating insulin levels reversed the impaired PIV and Ach-
stimulated vasodilation in 2-HCD mice (Fig. 4e, f).
Normalization of PIV in obese-prediabetic mice
requires adaptive PI3K-dependent NO signals
Since obese-prediabetic (4-HCD) mice had elevated
insulin (Table S1) and normalized adiponectin levels
(Fig. 1f), and PIV responses had become similar to age-
matched lean mice (Fig. 3a), we explored the possibility
that hyperinsulinemia-driven insulin signalling was
involved in the adaptive mechanism to normalize PIV. To
explore the requirement for a functional insulin receptor/
PI3K/AKT/NOS signalling pathway, we repeated PIV and
Ach-stimulated tests after administering pathway selective
inhibitors in 4-HCD mice. Here, PIV was sensitive to
NOS inhibition by LNNA and to the PI3K inhibitor,
wortmannin (Fig. 5b). In contrast, control mice remained
insensitive to wortmannin (Fig. 5a). This indicates the
recruitment of a PI3K-dependent NOS pathway in PIV
response of 4-HCD mice, while a PI3K-independent NOS
pathway remained functional in control lean mice. Inter-
estingly, wortmannin and NOS sensitivities were not
observed in Ach-stimulated vasodilation (Fig. 5c,d) in 4-
HCD mice (Fig. 5d). However, reactivity to Ach remained
indomethacin-sensitive (COX-dependent) in 4-HCD mice,
as in 2-HCD.
Enhanced PIV and acetylcholine-stimulated
vasodilation in obese-diabetic mice requires COX-2
In obese-diabetic (12-HCD) mice, both PIV and Ach-
stimulated vasodilation were significantly enhanced com-
pared to age-matched lean controls (Fig. 6a–d). Although
plasma insulin levels had elevated further (Table S1), adi-
ponectin levels were now similar to lean mice (Fig. 1f).
Here, PIV and Ach-stimulated responses were no longer
sensitive to PI3K inhibition by wortmannin in 12-HCD
(Fig. 6b). Nonetheless, enhanced PIV and Ach were sen-
sitive to combined inhibition of NOS and COX-1/2 inhi-
bition (LNNA+ Indo). Moreover, specific inhibition of
COX-2 by SC58125 alone resulted in the same magnitude
of inhibition as that achieved by dual LNNA+ Indo
(Fig. 6b, d). This suggests a major role for COX-2 in PIV
and Ach responses in 12-HCD mice.
BA 
DC 
4HCD 4HCD
W 
4HCD
LNNA
Indo 
4HCD
LNNA 
A
C
h-
in
du
ce
d 
LD
F
re
sp
on
se
 (%
) 
A
C
h-
in
du
ce
d 
LD
F
re
sp
on
se
 (%
) 
0
20
40
60
80
0
20
40
60
80
0
20
40
60
80
0
20
40
60
80
PI
V-
in
du
ce
d 
LD
F
re
sp
on
se
 (%
) 
PI
V-
in
du
ce
d 
LD
F
re
sp
on
se
 (%
) 
4C 4C
W 
4HCD 4HCD
W 
4HCD
LNNA
Indo 
4HCD
LNNA 
4C
LNNA 
4C
LNNA
Indo 
** **
**
*** ****
4C 4C
W 
4C
LNNA 
*
**
Fig. 5 Mechanisms involved in normalized PIV and impaired Ach
responsiveness in obese pre-diabetic mice. Mice were fed either
hypercaloric diet (HCD; black or dark grey bars) or standard chow (C;
white or light grey bars) for 4 weeks. Effects of selected pharmaco-
logical inhibitors were determined on microvascular response to local
pressure application (a, b) or Ach stimulation (c, d). Inhibitors
included PI3-kinase inhibitor, wortmannin (W; n= 7), nitric oxide
synthase inhibitor, L-NG-nitro-L-arginine (LNNA; n= 10) and
LNNA+ anti-inflammatory COX-1/2 inhibitor, indomethacin (LNNA
+ Indo; n= 5). Data represents mean ± SEM; *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001 vs. age-matched mice fed the same diet
but not treated with any inhibitor
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Fig. 6 Mechanisms involved in enhanced PIV and ACh responsive-
ness in obese diabetic mice. Mice were fed either hypercaloric diet
(HCD; black or dark grey bars) or standard chow (C; white or light
grey bars) for 12 weeks. Effects of selected pharmacological inhibitors
were determined on microvascular response to local pressure appli-
cation (a, b) or Ach stimulation (c, d). Inhibitors included PI3-kinase
inhibitor, wortmannin (W; n= 10), nitric oxide synthase inhibitor,
L-NG-nitro-L-arginine (LNNA) and anti-inflammatory COX-1/2
inhibitor, indomethacin (Indo; n= 7) and SC5812 (SC; n= 7). Data
represents mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001 vs. age-matched mice fed the same diet but not treated with any
inhibitor
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Discussion
Alterations in skin fragility and neurovascular function are
commonly associated with complications of diabetes and
include increased PU risk. However, the ability of overweight
and obese subjects to regulate protective neurovascular
mechanisms, such as PIV, is not known. Indeed, the impact of
increased dermal adiposity on dermal blood flow and
microvascular functionality is unclear. This systematic
investigation of disease ontogeny in a model of diet-induced
obesity and type 2 diabetes has identified temporal changes in
dermal tissue remodelling and microvascular functionality
that accompany increased adiposity, development of meta-
bolic deregulation and metaflammation. We confirm that
HCD fed mice develop obesity-associated type 2 diabetes
within 12 weeks (12-HCD) but this is preceded by at least two
distinct disease stages: ‘overweight-metabolically healthy’ (2-
HCD) and ‘obese-prediabetics’ (4-HCD). Importantly, we
show for the first time, that (1) dysfunction in dermal
microcirculation can be detected early during the onset of
diet-induced adiposity, when dermal adipose tissue is
increased but whole-body metabolic status remains minimally
altered; (2) progression to obesity-related type 2 diabetes is
accompanied by enhanced adaptive dermal vasodilatory
responses and (3) the adaptive microvascular responsiveness
involves a sequential switch from NO-dependent programme
to pro-inflammatory Cox2/PG programmes.
Our finding that dysfunction in dermal microvasculature
is an early feature of diet-induced adiposity in overweight-
metabolically healthy mice, is consistent with clinical and
pre-clinical studies, which demonstrate decreased reactivity
in other vascular beds following a single high-fat meal
[35–37]. Our observation of impaired responsiveness to two
stimuli (pressure and Ach) suggests that the primary defect
at this stage may be dysfunction in endothelial-derived NO
production. Indeed, reduced NO bioavailability has been
associated with acute hyperglycaemia-mediated oxidative
stress [38, 39]. However, unlike most studies of endothelial
dysfunction, our vasodilatory tests were performed in-situ
—in direct contact with innervated dWAT. Here, we
demonstrate that neurovascular and endothelial dysfunction
can be impacted early by altered adipokine production from
expanding dWAT. We show that impaired PIV in
overweight-metabolically healthy mice is linked to
decreased bioavailability of the vasoactive adipokine, adi-
ponectin. Although adipose expression of adiponectin is
reduced in obesity [9, 10], in our model we did not see a
sequential decrease of adiponection levels in HCD fed mice.
The transient elevation in adiponectin levels (in 4HCD
mice) is reminiscent of adiponectin resistance [9]. Interest-
ingly, impaired adiponectin signalling has been reported at
both receptor and post-receptor levels. For example, adi-
ponectin receptor 1 has been shown to be expressed on
adipose tissue-resident Tregs, and this expression is nega-
tively correlated with epididymal fat mass even in the
absence of significant changes in serum adiponectin [40].
Although dWAT-Tregs have not been investigated, it is
possible that in our model, increased adiposity also
associates with changes in local immunoregulation via
reduced adiponectin sensitivity of dWAT-resident Tregs.
Nonetheless, our study extends the understanding of adi-
ponectin involvement in PIV in the context of obesity-
linked endothelial dysfunction—previously reported only in
major blood vessels surrounded by perivascular adipose
tissue [13, 41–43]. Importantly, our finding that a single
application of either adiponectin or insulin can restore PIV
in these overweight mice supports the positive involvement
of these metabolic factors in dermal neurovascular func-
tionality and may offer new diagnostic and/or therapeutic
options for PU prevention in overweight individuals.
As increased adiposity progresses to obesity-related
metaflammation and type 2 diabetes, we observed
enhanced basal blood flow and increased microvasodilatory
responses in the dermis. This suggests that unlike the clear
pathogenic effects of type 1 diabetes on PIV [16, 19],
obesity can drive beneficial neurovascular adaptation in the
dermis even in the context of developing type 2 diabetes.
Hence, the presence of adiposity has a key role in main-
taining and augmenting the vasodilator capacity of dermal
microvessels. Moreover, these observations may explain
our previous finding that HCD fed obese-diabetic mice
become less prone to dermal ischaemia and skin lesions in
response to acute skin compression [8].
Mechanistically, a normalized PIV response in obese-
prediabetic mice (4-HCD) is not driven by parallel
improvements in Ach-induced vasodilation. Discordant
responses (between PIV and Ach) have previously been
reported [17, 44] and in our model, the adaptive PIV
response is likely mediated by the combined action of mild
hyperinsulinemia and improvements in adiponectin bioa-
vailability, which enlist PI3K- and NOS-dependent vaso-
dilation. It is noteworthy that unlike Ach-stimulated
vasodilation, PIV requires the additional release of
vasoactive neuromodulators such as CGRP, which act via
G-protein receptors to stimulate endothelial-NO production
[45]. Although, details of CGRP-mediated signal trans-
duction remain unclear, it has been reported to activate
AKT in a wortmannin-sensitive manner [46] and synergize
with inflammatory signals [47, 48]. Moreover, direct inter-
actions have been reported between G-protein receptors
[49, 50] and tyrosine kinase receptors (e.g. insulin receptor)
making it tempting to speculate that mild hyperinsulinemia
with insulin-sensitizing adiponectin (in obese-prediabetic
mice) is sufficient to activate a vasoactive pathway invol-
ving CGRP, IR-TK, PI3K, AKT and eNOS to promote
normalization PIV response. Future studies should address
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the putative participation of these pathways in regulating
PI3K-dependent NOS production during PIV.
Obese-diabetic mice (12-HCD) exhibit all the hallmarks of
type 2 diabetes and the metabolic syndrome. However,
despite these features, microvascular functionality in response
to both pressure and Ach is increased. Although this appears
to contrast with reports linking macrovascular endothelial
dysfunction to obesity, insulin resistance and type 2 diabetes
[20, 21, 51, 52], it is noteworthy that the latter alterations are
described for large and medium arteries and are based on
different in vivo techniques and stimuli such as flow-mediated
dilation (FMD), which activate alternative pathways to trigger
vasodilation [53, 54]. Mechanistically, the enhanced adaptive
vasodilatory responses in 12-HCD mice are PI3K-
independent and consistent with established endothelial
insulin resistance. Instead, the vasoactive mediators appear to
require Cox-2 activity, which generates the vasodilators PGI2
and PGE2 [55]. This is supported by reports showing rescue
of coronary endothelial function by COX-2 overexpression in
obese-insulin resistant mice [56, 57]. In addition, the
increased abundance of adipocytes and pro-inflammatory
(M1-like) macrophages are likely contributors to this adaptive
vascular response [58]. They not only promote local cytokine-
stimulated vasodilator production but are additional sources of
COX-2 activity that collectively may be sufficient to over-
come endothelial cell-specific dysfunction. Indeed, perivas-
cular adipose tissue surrounding the human saphenous vein
has been shown to attenuate noradrenalin-induced contraction
by releasing PGE2 and PGI2 [58]. Therefore, similar adaptive
mechanisms may exist to compensate for and maintain
functionality in dermal microvascular beds that lie in close
proximity to increasing adipose tissue during the progression
of obesity and diabetes.
Finally, it is noteworthy that by the end of the 12-week
study, lean control diet fed mice exhibited a number of age-
related changes that were similar to those observed in mice
fed HCD for 2 weeks. This included increase in body weight
(Fig. 1a, Table S1), food intake (Fig. 1b), adipocyte hyper-
plasia and hypertrophy (Fig. S2B), decreased plasma adipo-
nectin (Fig. 1f) and mild fasting hyperglycaemia (Table S1).
However, unlike the 2HCD group, these 23-week-old lean
mice only exhibited impairment in Ach-stimulated vasodila-
tion with a trend towards decreased PIV. Although residual
vasodilatory responses were no longer NO-dependent in both
groups of mice, there were some differences in the mechan-
isms involved in mediating residual vasodilation. Firstly,
residual Ach-dependent vasodilation did not gain sensitivity
to either COX1/2 or wortmannin inhibition as seen in 2HCD
mice. This suggests the involvement of additional age-related
mechanisms, e.g. endothelium-derived hyperpolarizing factor
(EDHF), can contribute to maintain relaxation of vascular
smooth muscle cells when NOS and COX are deficient to
produce NO and vasodilatory prostanoids [28]. However, PIV
seems to be partly compensated for by the recruitment of
PI3K-dependent (wortmannin-sensitive) signals. Taken toge-
ther, this data further supports the notion that distinct adaptive
mechanisms can be recruited to maintain PIV in the face of
impaired endothelial function.
In summary, we have demonstrated that increased dermal
adiposity, associated metaflammation and metabolic dys-
function drive disease stage-dependent adaptations in der-
mal microvascular reactivity. The involvement of distinct
adaptive vasodilatory signals may prove useful to inform
better diagnostics to assess PU risk in overweight and obese
subjects with or without altered metabolic profiles.
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